Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: The role of tamoxifen and radiotherapy

Journal of Urology

Volumn 174, Issue 6, 2005, Pages 2197-2203

  Di Lorenzo, Giuseppe ^a   Perdoná, Sisto ^b   De Placido, Sabino ^a   D'Armiento, Massimo ^c   Gallo, Antonio ^b   Damiano, Rocco ^d   Pingitore, Domenico ^e   Gallo, Luigi ^b   De Sio, Marco ^c   Autorino, Riccardo ^c,f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e Ospedale Ciaccio   (Italy)

^f NONE   (Italy)

Author keywords

Gynecomastia; Pain; Prostate; Prostatectomy; Quality of life

Indexed keywords

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GYNECOMASTIA; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MONOTHERAPY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL FUNCTION; SKIN IRRITATION;

EID: 27744476741     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000181824.28382.5c     Document Type: Article

References (19)

1. Amling, C. L., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol, 164: 101, 2000
2. Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., Van Poppel, H., Tammela, T. L. J. et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164: 1579, 2000
3. Boccardo, F., Rubagotti, A., Barichello, M., Battaglia, M., Carmignani, G., Comeri, G. et al: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol, 17: 2027, 1999
4. Chatelain, C., Fourcade, R. O. and Delchambre, J.: Bicalutamide versus combined androgen blockade: open French multicentre trial in patients with metastatic prostate cancer. Br J Urol, 80: 283, abstract 1111, 1997
5. See, W. A., Wirth, M. P., McLeod, D. G, Iverson, P., Klimberg, I., Gleason, D. et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
6. Wirth, M. P., See, W. A., McLeod, D. G., Iversen, P., Morris, T. and Carroll, K.: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of early prostate cancer program at median followup of 5.4 years. J Urol, 172:1865, 2004
7. McLeod, D. G. and Iversen, P.: Gynecomastia in patients with prostate cancer: a review of treatment options. Urology, 56: 713, 2000
8. Dicker, A. P.: The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol, 4: 30, 2003
9. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J. et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85: 365, 1993
10. Rosen, E. L., Teloken, C., Sogari, P. R. and Vargas Souto, C. A.: The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res, 14: 245, 2002
11. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457, 1958
12. Boccardo, F., Rubagotti, A., Battaglia, M., Di Tonno, P., Selvaggi, F. P., Conti, G. et al: Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol, 23: 808, 2005
13. Saltzstein, D., Sieber, P., Morris, T. and Gallo, J.: Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis, 8: 75, 2005
14. Tyrrell, C. J., Payne, H., Tammela, T. L., Bakke, A., Lodding, P., Goedhals, L. et al: Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys, 60: 476, 2004
15. Van Poppel, H., Tyrrell, C. J., Haustermans, K, Cangh, P. V., Keuppens, F., Colombeau, P. et al: Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol, 47: 587, 2005
16. Eaton, A. C., Makris, A. and Makris, A.: Once weekly tamoxifen in the prevention of gynaaecomastia and breast pain secondary to bicalutamide therapy. J Urol, suppl., 171: 282, abstract 1069, 2004
17. Widmark, A., Fossa, S. D., Lundmo, P., Damber, J. E., Vaage, S., Damber, L. et al: Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology, 61: 145, 2003
18. Joiner, M. C.: The linear-quadratic approach to fractionation. In: Basic Clinical Radiobiology. Edited by G. C. Steel. London: Edward Arnold, pp. 55-64, 1993
19. Kunkler, I.: Adjuvant irradiation for breast cancer. BMJ, 320: 1485, 2000